Denali Therapeutics Inc. 4

Denali Therapeutics Inc. Chief Medical Officer Peter Scott Chin sold 1,654 shares of common stock at about $22.29 per share to cover taxes related to vested RSUs.

On September 4, 2026, Denali Therapeutics Inc. Chief Medical Officer Peter Scott Chin sold 1,654 shares of Denali Therapeutics common stock at a weighted average price of approximately $22.29 per share, for total proceeds of about $36,850, in a transaction explicitly described as a sale to cover tax obligations arising from the settlement of previously vested restricted stock units. Following this tax-related sale, he beneficially owned 204,538 shares of common stock, which includes 142,845 unvested RSUs and 1,790 shares previously acquired under the company’s ESPP, implying an ongoing substantial equity stake whose estimated market value is roughly $4.56 million based on the reported sale price. The sale price reflects a narrow trading range between $22.28 and $22.29, and the transaction appears to be a routine, compensation-linked disposition rather than a discretionary reduction in his overall investment position.

Filing Facts

CIK

1714899

Ticker

DNLI

Form

4

Source Type

fda

Accession

0002124755-26-000007

Alert Tier

5